DOCSLIB.ORG

PRODUCT CATALOGUE 2021 Available on Product Known Teva Tech US EU Japan Korea Therapeutic Api IP File*** DMF DMF DMF DMF Area**

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PRODUCT CATALOGUE 2021 Available on Product Known Teva Tech US EU Japan Korea Therapeutic Api IP File*** DMF DMF DMF DMF Area** S NH2 N N O O O HN CH OH 3 N O SO3H PRODUCT CATALOGUE 2021 Available on www.teva-api.com Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** A ABALOPARATIDE Osteoporosis ABEMACICLIB Oncology ABIRATERONE ACETATE Oncology ACALABRUTINIB Oncology AFATINIB Oncology ALCLOMETASONE DIPROPIONATE Dermatology ALLOPURINOL Rheumatology CEP AMCINONIDE Dermatology AMITRIPTYLINE HCl Neurology - Psychiatry CEP ANASTROZOLE Oncology CEP ANIDULAFUNGIN Infectious disease APALUTAMIDE* Oncology Coagulation APIXABAN inhibitors APREMILAST* Psoriasis ARIPIPRAZOLE* Neurology-Psychiatry CEP ATOMOXETINE HCl Neurology-Psychiatry ATORVASTATIN CALCIUM Lipid lowering CEP Preterm labor ATOSIBAN ACETATE prevention ATRACURIUM BESYLATE Muscle relaxant CEP AZACITIDINE Oncology AZITHROMYCIN DIHYDRATE Infectious disease CEP AZITHROMYCIN MONOHYDRATE Infectious disease CEP AZTREONAM* Infectious disease B BALOXAVIR Antiviral 2 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** BARICITINIB Rheumatology BECLOMETHASONE DIPROPIONATE Respiratory CEP BETAMETHASONE ACETATE Inflammation BETAMETHASONE BASE Dermatology CEP BETAMETHASONE DIPROPIONATE Dermatology CEP BETAMETHASONE VALERATE Dermatology CEP BICALUTAMIDE Oncology CEP BIVALIRUDIN Hematology BLEOMYCIN SULFATE Oncology BORTEZOMIB Oncology BREXANOLONE Neurology-Psychiatry BREXPIPRAZOLE Neurology-Psychiatry BROMOCRIPTINE MESYLATE Cardiovascular CEP BUDESONIDE Respiratory CEP BUPRENORPHINE BASE Neurology-Psychiatry CEP BUPRENORPHINE HCl Neurology-Psychiatry CEP BUTORPHANOL TARTRATE Analgesic C CABAZITAXEL Oncology Prolactinoma CABERGOLINE treatment CEP CALCIPOTRIENE* Immunology CEP Endocrinology CALCITRIOL & Metabolism CEP CANDESARTAN CILEXETIL Cardiovascular CEP CARBIDOPA Parkinson CEP * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 3 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** CARBOPLATIN Oncology CEP CARFILZOMIB Oncology CARVEDILOL PHOSPHATE Cardiovascular CASPOFUNGIN ACETATE Infectious disease Endocrinology CHLORMADINONE ACETATE & Metabolism CICLOSPORINE Immunology CEP Coagulation CILOSTAZOL inhibitors Endocrinology CINACALCET HCl & Metabolism CISATRACURIUM BESYLATE Muscle relaxant CEP CISPLATIN Oncology CEP CLARITHROMYCIN Infectious disease CEP CLASCOTERONE Dermatology CLOBETASOL PROPIONATE Dermatology CEP Coagulation CLOPIDOGREL BISULFATE* inhibitors CEP CRISABOROLE Dermatology Endocrinology CYPROTERONE ACETATE & Metabolism CEP Coagulation D DABIGATRAN ETEXILATE inhibitors DALBAVANCIN Infectious disease DASATINIB* Oncology DAUNORUBICIN HCl Oncology CEP DEFERASIROX Hematology DEFEROXAMINE MESYLATE Hematology CEP DEPRODONE PROPIONATE Dermatology DESLORATADINE Allergology DESMOPRESSIN ACETATE Nocturia CEP 4 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** DESONIDE Dermatology DESOXYCORTICOSTERONE Immunology DESVENLAFAXINE BASE Neurology-Psychiatry DESVENLAFAXINE SUCCINATE Neurology-Psychiatry DEXAMETHASONE - 17 VALERATE Inflammation DEXRAZOXANE (ICRF) Cardiovascular DIAZOXIDE Cardiovascular DIFLORASONE DIACETATE Dermatology DIFLUPREDNATE Ophthalmology DIHYDROERGOTAMINE MESYLATE Migraine CEP DIHYDROERGOTOXINE MESYLATE Neurology-Psychiatry CEP DILTIAZEM HCl Cardiovascular CEP DIMETHYL FUMARATE Immunology DIROXIMEL FUMARATE Immunology DOCETAXEL Oncology DOCOSANOL Antiviral DONEPEZIL HCl* Neurology-Psychiatry DORZOLAMIDE HCl Ophthalmology CEP DOXEPIN HCl Neurology-Psychiatry CEP Endocrinology DOXERCALCIFEROL & Metabolism DOXORUBICIN HCl Oncology CEP Endocrinology DROSPIRENONE & Metabolism CEP * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 5 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** Coagulation E EDOXABAN TOSYLATE inhibitors ELAGOLIX Genitourinary ELETRIPTAN HBr Migraine ELTROMBOPAG OLAMINE Hematology ELUXADOLINE Gastroenterology EMPAGLIFLOZIN Diabetes EPIRUBICIN HCl Oncology CEP EPTIFIBATIDE Hematology Postpartum ERGOMETRINE (ERGONOVINE) MALEATE haemorrhage CEP ERGOTAMINE TARTRATE Migraine CEP ERLOTINIB HCl* Oncology ESZOPICLONE Neurology-Psychiatry ETODOLAC Inflammation CEP ETOPOSIDE Oncology CEP EZETIMIBE Lipid lowering F FAMCICLOVIR Antiviral FEBUXOSTAT Rheumatology FINGOLIMOD HCl Immunology CEP FLUDARABINE PHOSPHATE Oncology CEP FLUDROCORTISONE ACETATE Genitourinary FLUNISOLIDE* Respiratory FLUOCINOLONE ACETONIDE* Dermatology FLUOCINONIDE* Dermatology FLUOROMETHOLONE ACETATE Ophthalmology FLUOROMETHOLONE BASE Ophthalmology 6 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** FLUOROURACIL - (5FU) Oncology CEP FLUOXETINE HCl Neurology-Psychiatry CEP FLUTICASONE FUROATE Respiratory FLUTICASONE PROPIONATE Respiratory CEP FLUVASTATIN SODIUM Lipid lowering CEP FORMOTEROL FUMARATE Respiratory CEP FULVESTRANT Oncology CEP FUROSEMIDE Cardiovascular CEP G GALANTAMINE HBr Neurology-Psychiatry CEP GEMCITABINE HCl Oncology CEP Endocrinology GLYCEROL PHENYLBUTYRATE & Metabolism H HALOPERIDOL Neurology-Psychiatry HALOPERIDOL DECANOATE Neurology-Psychiatry HYDROCHLOROTHIAZIDE* Cardiovascular CEP I IBRUTINIB Oncology ICATIBANT ACETATE Angioedema IDARUBICIN HCl Oncology IMATINIB MESYLATE* Oncology CEP IMIPRAMINE HCl Neurology-Psychiatry CEP IMIQUIMOD Dermatology IRBESARTAN Cardiovascular CEP IVOSIDENIB Oncology IXAZOMIB CITRATE Oncology * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 7 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** L LABETALOL HCl Cardiovascular CEP LAMOTRIGINE Epileptic CEP LANSOPRAZOLE Gastroenterology CEP LAROTRECTINIB Oncology LATANOPROSTENE BUNOD Ophthalmology LEDIPASVIR* Antiviral LETERMOVIR Antiviral LETROZOLE Oncology LEVOFLOXACIN Infectious disease LEVOSALBUTAMOL HCl (LEVALBUTEROL) Respiratory LIFITEGRAST Ophthalmology LINACLOTIDE Gastroenterology LINAGLIPTIN Diabetes LOPERAMIDE HCl Gastroenterology CEP LORLATINIB Oncology LOSARTAN POTASSIUM AZIDE Cardiovascular CEP LOVASTATIN Lipid lowering CEP LURASIDONE HCl Neurology-Psychiatry M MACITENTAN Cardiovascular Endocrinology MAXACALCITOL & Metabolism Endocrinology MEDROXYPROGESTERONE ACETATE & Metabolism CEP Endocrinology MEGESTROL ACETATE & Metabolism CEP MEMANTINE HCl Neurology-Psychiatry METHYLDOPA Cardiovascular CEP 8 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** Postpartum METHYLERGONOVINE MALEATE haemorrhage CEP METHYLPREDNISOLONE HEMISUCCINATE Inflammation METOPROLOL SUCCINATE Cardiovascular CEP METOPROLOL TARTRATE Cardiovascular CEP MICAFUNGIN SODIUM Infectious disease MIDOSTAURIN* Oncology MITOMYCIN Oncology CEP MOMETASONE FUROATE* Respiratory CEP MONTELUKAST SODIUM* Respiratory CEP MUPIROCIN* Infectious disease CEP MUPIROCIN CALCIUM Infectious disease CEP MYCOPHENOLATE MOFETIL Immunology CEP MYCOPHENOLATE SODIUM Immunology N NABUMETONE Inflammation CEP NERATINIB MALEATE Oncology NETARSUDIL MESYLATE Ophthalmology NICERGOLINE Cardiovascular CEP NIFEDIPINE Cardiovascular CEP NILOTINIB FUMARATE Oncology NILOTINIB HCl Oncology NILOTINIB TARTRATE Oncology NINTEDANIB ESYLATE Oncology NIRAPARIB TOSYLATE Oncology * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 9 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** NITROFURANTOIN* Infectious disease Endocrinology NOMEGESTROL ACETATE & Metabolism CEP Endocrinology NORGESTIMATE & Metabolism O OBETICHOLIC ACID Immunology Endocrinology OCTREOTIDE ACETATE & Metabolism OLANZAPINE Neurology - Psychiatry CEP OLMESARTAN MEDOXOMIL Cardiovascular CEP OLODATEROL HCl Respiratory OMEPRAZOLE Gastroenterology CEP ONDANSETRON BASE Gastroenterology ONDANSETRON HCl Gastroenterology CEP ORITAVANCIN Infectious disease OSIMERTINIB MESYLATE Oncology OXALIPLATIN Oncology CEP P PACLITAXEL Oncology CEP PALBOCICLIB Oncology PALIPERIDONE PALMITATE Neurology - Psychiatry PALONOSETRON HCl* Gastroenterology - Oncology PANCURONIUM BROMIDE Muscle relaxant CEP Endocrinology PARICALCITOL & Metabolism PEMETREXED* Oncology PERAMPANEL Epileptic PERGOLIDE MESYLATE Parkinson CEP PIOGLITAZONE HCl Diabetes PLECANATIDE Gastroenterology 10 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** PRALATREXATE
Load more

Recommended publications
  • Betamethasone
    Betamethasone Background Betamethasone is a potent, long-acting, synthetic glucocorticoid widely used in equine veterinary medicine as a steroidal anti-inflammatory.1 It is often administered intra-articularly for control of pain associated with inflammation and osteoarthritis.2 Betamethasone is a prescription medication and can only be dispensed from or upon the request of a http://en.wikipedia.org/wiki/Betamethasone#/media/File:Betamethasone veterinarian. It is commercially available .png in a variety of formulations including BetaVet™, BetaVet Soluspan Suspension® and Betasone Aqueous Suspension™.3 Betamethasone can be used intra-articularly, intramuscularly, by inhalation, and topically.4 When administered intra-articularly, it is often combined with other substances such as hyaluronan.5 Intra-articular and intramuscular dosages range widely based upon articular space, medication combination protocol, and practitioner preference. Betamethasone is a glucocorticoid receptor agonist which binds to various glucocorticoid receptors setting off a sequence of events affecting gene transcription and the synthesis of proteins. These mechanisms of action include: • Potential alteration of the G protein-coupled receptors to interfere with intracellular signal transduction pathways • Enhanced transcription in many genes, especially those involving suppression of inflammation. • Inhibition of gene transcription – including those that encode pro-inflammatory substances. The last two of these are considered genomic effects. This type of corticosteroid effect usually occurs within hours to days after administration. The genomic effects persist after the concentrations of the synthetic corticosteroid in plasma are no longer detectable, as evidenced by persistent suppression of the normal production of hydrocortisone following synthetic corticosteroid administration.6 When used judiciously, corticosteroids can be beneficial to the horse.
    [Show full text]
  • Oxytocin Versus Methylergometrine in the Active Management of Third Stage of Labour
    Open Journal of Obstetrics and Gynecology, 2014, 4, 666-671 Published Online August 2014 in SciRes. http://www.scirp.org/journal/ojog http://dx.doi.org/10.4236/ojog.2014.411093 Oxytocin versus Methylergometrine in the Active Management of Third Stage of Labour Ajantha Boopathi1*, Sujir Radhakrishnan Nayak2, Arun Rao2, Bharathi Rao2 1Andal Hospital, Cuddalore, India 2Department of Obstetrics and Gynecology, Kasturba Medical College (A Constituent of Manipal University), Mangalore, India Email: *[email protected] Received 19 June 2014; revised 15 July 2014; accepted 10 August 2014 Copyright © 2014 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Objective: To compare the efficacy of Oxytocin versus Methylergometrine in active management of third stage of labour in reducing risk of postpartum hemorrhage. Methods: This study was carried out by randomly assigning into two groups with 150 women in each group. Group 1 included pa- tients who received injection Oxytocin 10 IU intramuscular within one minute of the birth of the baby. Injection Methylergometrine (0.2 mg) was given intravenously at the delivery of anterior shoulder of the baby to women in Group 2. Outcome measures were the duration of third stage, blood loss, pre and post-delivery hematocrit, side effects and incidence of PPH. Statistical analysis was done using Chi square test, Fischers test, Mann Whitney test, and t test. p < 0.05 was consi- dered significant. Results: Mean duration of third stage of labour, mean blood loss, post-delivery fall in hematocrit and need for additional uterotonics were significantly less in the Group 2.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Biased Ligands Differentially Shape the Conformation of The
    International Journal of Molecular Sciences Article Biased Ligands Differentially Shape the Conformation of the Extracellular Loop Region in 5-HT2B Receptors Katrin Denzinger, Trung Ngoc Nguyen, Theresa Noonan, Gerhard Wolber and Marcel Bermudez * Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Strasse 2-4, 14195 Berlin, Germany; [email protected] (K.D.); [email protected] (T.N.N.); [email protected] (T.N.); [email protected] (G.W.) * Correspondence: [email protected] Received: 22 November 2020; Accepted: 18 December 2020; Published: 20 December 2020 Abstract: G protein-coupled receptors are linked to various intracellular transducers, each pathway associated with different physiological effects. Biased ligands, capable of activating one pathway over another, are gaining attention for their therapeutic potential, as they could selectively activate beneficial pathways whilst avoiding those responsible for adverse effects. We performed molecular dynamics simulations with known β-arrestin-biased ligands like lysergic acid diethylamide and ergotamine in complex with the 5-HT2B receptor and discovered that the extent of ligand bias is directly connected with the degree of closure of the extracellular loop region. Given a loose allosteric coupling of extracellular and intracellular receptor regions, we delineate a concept for biased signaling at serotonin receptors, by which conformational interference with binding pocket closure restricts the signaling repertoire of the receptor. Molecular docking studies of biased ligands gathered from the BiasDB demonstrate that larger ligands only show plausible docking poses in the ergotamine-bound structure, highlighting the conformational constraints associated with bias. This emphasizes the importance of selecting the appropriate receptor conformation on which to base virtual screening workflows in structure-based drug design of biased ligands.
    [Show full text]
  • WO 2010/099522 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 September 2010 (02.09.2010) WO 2010/099522 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/4164 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4045 (2006.01) A61K 31/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2010/025725 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 1 March 2010 (01 .03.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/156,129 27 February 2009 (27.02.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, HELSINN THERAPEUTICS (U.S.), INC.
    [Show full text]
  • 1. Generic Names Levosalbutamol 0.25G Ambroxol 7.5Mg
    1. Generic Names Levosalbutamol 0.25g Ambroxol 7.5mg Guaiphenesin 12.5 mg 2. Qualitative and Quantitative Composition Each ml contains Levosalbutamol 0.25g Ambroxol 7.5mg Guaiphenesin 12.5 mg 3. Dosage form and strength Oral drop solution containing Levosalbutamol 0.25g, Ambroxol 7.5mg, Guaiphenesin 12.5 mg. 4. Clinical particulars 4.1 Therapeutic indication Kofarest-PD drops is indicated for the treatment of productive cough associated with bronchospasm in conditions such as bronchitis and bronchial asthma as well as all conditions associated with tenacious mucus, wheezing and chest congestion. 4.2 Posology and method of administration The usual recommended dose of KOFAREST-PD Drops in children is: 1-2 years age: 0.8 ml thrice a day 2-3 years age: 1.2 ml thrice a day. 4.3 Contraindication Kofarest-PD drops are contraindicated in patients with hypersensitivity to any ingredient of the formulation. 4.4 Special warnings and precautions for use While treating cough as a symptom, it is important to make every effort to determine and treat appropriately the underlying cause, such as a specific infection. Caution should be observed while prescribing Kofarest-PD drops to children with hypertension, cardiovascular disease, uncontrolled juvenile diabetes mellitus, hyperthyroidism, and seizures or in patients who are unusually hypersensitive to sympathomimetic amines. 4.5 Drug interactions Hypokalaemia with high doses of ß2 -agonists may result in increased susceptibility to digitalis induced cardiac arrhythmias. Hypokalaemia may be enhanced by concomitant administration of aminophylline or other xanthine, corticosteroids or by diuretic therapy. Other sympathomimetic bronchodilators or epinephrine should not be used concomitantly with salbutamol, since their combined effect on the cardiovascular system may be deleterious to the patient.
    [Show full text]
  • Risk Assessment of Argyreia Nervosa
    Risk assessment of Argyreia nervosa RIVM letter report 2019-0210 W. Chen | L. de Wit-Bos Risk assessment of Argyreia nervosa RIVM letter report 2019-0210 W. Chen | L. de Wit-Bos RIVM letter report 2019-0210 Colophon © RIVM 2020 Parts of this publication may be reproduced, provided acknowledgement is given to the: National Institute for Public Health and the Environment, and the title and year of publication are cited. DOI 10.21945/RIVM-2019-0210 W. Chen (author), RIVM L. de Wit-Bos (author), RIVM Contact: Lianne de Wit Department of Food Safety (VVH) [email protected] This investigation was performed by order of NVWA, within the framework of 9.4.46 Published by: National Institute for Public Health and the Environment, RIVM P.O. Box1 | 3720 BA Bilthoven The Netherlands www.rivm.nl/en Page 2 of 42 RIVM letter report 2019-0210 Synopsis Risk assessment of Argyreia nervosa In the Netherlands, seeds from the plant Hawaiian Baby Woodrose (Argyreia nervosa) are being sold as a so-called ‘legal high’ in smart shops and by internet retailers. The use of these seeds is unsafe. They can cause hallucinogenic effects, nausea, vomiting, elevated heart rate, elevated blood pressure, (severe) fatigue and lethargy. These health effects can occur even when the seeds are consumed at the recommended dose. This is the conclusion of a risk assessment performed by RIVM. Hawaiian Baby Woodrose seeds are sold as raw seeds or in capsules. The raw seeds can be eaten as such, or after being crushed and dissolved in liquid (generally hot water).
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Zirtek Plus Decongestant 5mg/120mg Prolonged Release Tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet provides 5 mg cetirizine dihydrochloride for immediate release, and 120 mg pseudoephedrine hydrochloride for prolonged release. Excipients with known effect: one tablet contains 43.23 mg lactose monohydrate For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Prolonged release tablet. White to off-white, round, biconvex circle-embossed, film-coated tablet, having a circular logo on one side. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Cetirizine-pseudoephedrine is indicated for the treatment of symptoms such as nasal congestion, sneezing, rhinorrhoea, and nasal and ocular pruritus associated with seasonal or perennial allergic rhinitis. Cetirizine-pseudoephedrine should be administered when the anti-allergic properties of cetirizine dihydrochloride and the nasal decongestant activity of pseudoephedrine hydrochloride are desired. 4.2 Posology and method of administration Posology Adults One tablet two times a day (morning and evening), corresponding to the maximum recommended dose of 10 mg of cetirizine dihydrochloride and 240 mg of pseudoephedrine hydrochloride daily. Special populations Paediatric population Adolescents from 12 years of age and above: 1 tablet two times a day (morning and evening), with or without food. Children under 12 years of age: the use of the product is contraindicated (see sections 4.3 and 4.4). Renal impairment The dose should be reduced to 1 tablet daily in patients with moderate renal insufficiency. Hepatic impairment The dose should be reduced to 1 tablet daily in patients with moderate hepatic insufficiency.
    [Show full text]
  • Supplementary Materials 07/09/2017
    SMART Adolescent manuscript: Supplementary materials 07/09/2017 Supplementary materials Methods Definition and calculation of severe exacerbations The first three studies conducted 10-12, defined severe exacerbations as the need for oral corticosteroid (OCS) and/or hospitalisation/emergency room care due to asthma and/or a decrease in peak expiratory flow (PEF) of ≥30% on two consecutive days compared with the run-in period. In these studies, exacerbations were to be treated with a 10-day OCS course; an exacerbation lasting >10 days was considered a new exacerbation on the 11th day. Based on this experience, the later three studies 13-15 did not include falls in PEF in the exacerbation definition, nor this stipulated OCS treatment time, defining a severe exacerbation as the need for OCS for ≥3 days and/or hospitalisation/emergency room care due to asthma worsening. For the purpose of this analysis, we defined a severe exacerbation as the need for OCS (for ≥3 days 10-12) and/or hospitalisation/emergency room care due to asthma worsening; to align with this definition, data from 3 of the included studies 13-15 were reanalysed to exclude PEF fall from the exacerbation definition. 1 SMART Adolescent manuscript: Supplementary materials 07/09/2017 Literature review to identify any additional studies We conducted a review to identify any additional randomised controlled trials (RCTs) evaluating a combination of inhaled corticosteroids (ICS) and a rapid- acting bronchodilator in a single inhaler for both maintenance and as-needed relief of symptoms
    [Show full text]
  • Methysergide Art. 31
    20 February 2014 EMA/276466/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pursuant to Article 31 of Directive 2001/83/EC Methysergide containing medicinal products International non-proprietary name: methysergide Procedure No. EMEA/H/A-31/1335 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical efficacy .................................................................................................... 3 2.2.1. Results ............................................................................................................. 4 2.2.2. Discussion ........................................................................................................ 9 2.3. Clinical safety ...................................................................................................
    [Show full text]
  • Therapeutic Drug Class
    BUREAU FOR MEDICAL SERVICES EFFECTIVE WEST VIRGINIA MEDICAID PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 07/01/2018 This is not an all-inclusive list of available covered drugs and includes only Version 2018.3e managed categories. Refer to cover page for complete list of rules governing this PDL. • Prior authorization for a non-preferred agent in any class will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. • Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) • Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. • PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. • The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
    [Show full text]